Karl Mann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karl Mann has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Alexander Diehl
4 shared publicationsBernhard Croissant
4 shared publicationsHelmut Nakovics
4 shared publications- Andreas Heinz
Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany
2 shared publications - Falk Kiefer
Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
2 shared publications Lucie Severa
2 shared publications
Latest Publications
- 31 December 2009
- Published by Elsevier in Psychosomatics
- Vol. 50 (6) , 599-604
Consultation–Liaison Psychiatry in General Hospitals: Improvement in Physicians’ Detection Rates of Alcohol Use Disorders
- 31 December 2009
- Published by Elsevier in Psychosomatics
- Vol. 50 (6) , 599-604
Consultation–Liaison Psychiatry in General Hospitals: Improvement in Physicians’ Detection Rates of Alcohol Use Disorders
- 1 January 2008
- Vol. 22 (4) , 243-51
[Recent results in relaps prevention of alcoholism with Disulfiram].
For more than 50 years, disulfiram has been approved for the treatment of chronic alcohol dependence. In the last years there has been observed an increase in the prescription of disulfiram in germany. It acts as a psychological deterrence of a possible disulfiram-alcohol reaction. This paper describes the current clinical impact and possible future of disulfiram. Clinical trials using disulfiram for the treatment of alcohol dependence were discussed. Furthermore, the options of combining disulfiram with novel anti-craving agents were considered. Moreover, experiences and results of a cross section of the Mannheimer Disulfiram program will be presented. Nowadays there exists consent in the matter that Disulfiram should only be adminsitered as part of a comprehensive therapy program, this means in the context of an intake under medical supervision. This paper is supposed to help estimate the value of disulfiram in recent addiction medicine.
- 1 January 2008
- Vol. 22 (4) , 243-51
[Recent results in relaps prevention of alcoholism with Disulfiram].
For more than 50 years, disulfiram has been approved for the treatment of chronic alcohol dependence. In the last years there has been observed an increase in the prescription of disulfiram in germany. It acts as a psychological deterrence of a possible disulfiram-alcohol reaction. This paper describes the current clinical impact and possible future of disulfiram. Clinical trials using disulfiram for the treatment of alcohol dependence were discussed. Furthermore, the options of combining disulfiram with novel anti-craving agents were considered. Moreover, experiences and results of a cross section of the Mannheimer Disulfiram program will be presented. Nowadays there exists consent in the matter that Disulfiram should only be adminsitered as part of a comprehensive therapy program, this means in the context of an intake under medical supervision. This paper is supposed to help estimate the value of disulfiram in recent addiction medicine.
- 29 March 2006
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 30 (4) , 630-635
A Pilot Study of Oxcarbazepine Versus Acamprosate in Alcohol‐Dependent Patients
Objectives: This pilot study has been designed to collect preliminary data on the use of a new antiepileptic drug in the management of alcoholic patients. Oxcarbazepine (OXC) blocks voltage‐sensitive sodium channels. Its metabolite reduces high‐voltage–activated calcium currents in striatal and cortical neurons, thus reducing glutamatergic transmission at corticostriatal synapses. This reduction is of interest in the treatment of alcohol dependence, as acamprosate (ACP) modulates NMDA receptors, resulting in an inhibition of glutamatergic transmission. Furthermore, OXC has revealed a mood‐stabilizing effect in bipolar affective disorders. We have compared OXC with ACP in relapse prevention in recently withdrawn alcohol‐dependent patients. Methods: We investigated the efficacy and safety of OXC (vs ACP) by conducting a 24‐week randomized, parallel‐group, open‐label, clinical trial on 30 acutely detoxified alcoholic patients. Survival analyses (Kaplan–Meier) were performed to look for evidence of a longer “survival” of patients receiving OXC. We assessed time to first severe relapse and additional secondary endpoints. Results: After withdrawal, time to severe relapse and time to first consumption of any ethanol by OXC patients were not longer than for ACP patients. Abstinent patients in both study groups showed a significantly lower obsessive compulsive drinking scale—German version (OCDS‐G) than relapsed patients. No undesired effects occurred when OXC patients consumed alcohol. Conclusion: Our findings indicate that it could be worthwhile to test relapse prevention using OXC in an adequate sample. While the current sample size clearly limits further conclusions from this pilot study, it is noteworthy that OXC is well tolerated, even when alcohol is on board. Thus, in medication‐based relapse prevention, OXC could be a promising alternative for alcoholic patients unable to benefit from ACP or naltrexone or those who have affective liability. OXC certainly merits a larger placebo‐controlled trial.
- 29 March 2006
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 30 (4) , 630-635
A Pilot Study of Oxcarbazepine Versus Acamprosate in Alcohol‐Dependent Patients
Objectives: This pilot study has been designed to collect preliminary data on the use of a new antiepileptic drug in the management of alcoholic patients. Oxcarbazepine (OXC) blocks voltage‐sensitive sodium channels. Its metabolite reduces high‐voltage–activated calcium currents in striatal and cortical neurons, thus reducing glutamatergic transmission at corticostriatal synapses. This reduction is of interest in the treatment of alcohol dependence, as acamprosate (ACP) modulates NMDA receptors, resulting in an inhibition of glutamatergic transmission. Furthermore, OXC has revealed a mood‐stabilizing effect in bipolar affective disorders. We have compared OXC with ACP in relapse prevention in recently withdrawn alcohol‐dependent patients. Methods: We investigated the efficacy and safety of OXC (vs ACP) by conducting a 24‐week randomized, parallel‐group, open‐label, clinical trial on 30 acutely detoxified alcoholic patients. Survival analyses (Kaplan–Meier) were performed to look for evidence of a longer “survival” of patients receiving OXC. We assessed time to first severe relapse and additional secondary endpoints. Results: After withdrawal, time to severe relapse and time to first consumption of any ethanol by OXC patients were not longer than for ACP patients. Abstinent patients in both study groups showed a significantly lower obsessive compulsive drinking scale—German version (OCDS‐G) than relapsed patients. No undesired effects occurred when OXC patients consumed alcohol. Conclusion: Our findings indicate that it could be worthwhile to test relapse prevention using OXC in an adequate sample. While the current sample size clearly limits further conclusions from this pilot study, it is noteworthy that OXC is well tolerated, even when alcohol is on board. Thus, in medication‐based relapse prevention, OXC could be a promising alternative for alcoholic patients unable to benefit from ACP or naltrexone or those who have affective liability. OXC certainly merits a larger placebo‐controlled trial.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 42A
QUETIAPINE IN ALCOHOL RELAPSE PREVENTION - A CASE SERIES.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 42A
QUETIAPINE IN ALCOHOL RELAPSE PREVENTION - A CASE SERIES.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 41A
OXCARBAZEPINE IN ALCOHOL RELAPSE PREVENTION ??? A RANDOMIZED OPEN PILOT STUDY.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (Supplement) , 41A
OXCARBAZEPINE IN ALCOHOL RELAPSE PREVENTION ??? A RANDOMIZED OPEN PILOT STUDY.